RYBREVANT FASPRO™ + chemotherapy
and RYBREVANT® + chemotherapy
are 2nd treatments for people with
EGFR+* NSCLC.
Actor portrayals.
What to expect with RYBREVANT FASPRO™–based or RYBREVANT®-based treatments
Get more information about the treatment, possible side effects, and how to prepare.
*Exon 19 deletion or exon 21 L858R substitution mutations.
EGFR+, mutated epidermal growth factor receptor; NSCLC, non–small cell lung cancer.
Facing lung cancer comes with many challenges, but you're not alone.
There are many groups that can help support people living with lung cancer as well as their loved ones.
Once prescribed RYBREVANT FASPRO™ or RYBREVANT®, connect with a Care Navigator for your support needs.
